Frequency of Sustained Virologic Response in Hepatitis C Positive, Treatment Naïve Patients on Sofosbuvir and Daclatasvir
DOI:
https://doi.org/10.37762/jgmds.10-3.439Keywords:
Hepatitis C, Sofosbuvir, Daclatasvir, Treatment , Sustained Virologic ResponseAbstract
OBJECTIVES
To measure the frequency of sustained virologic response in Hepatitis C positive, treatment naïve patients on Sofosbuvir and Daclatasvir.
METHODOLOGY
This descriptive study was conducted in the Department of Medicine, Khyber Teaching Hospital Peshawar from 15th May 2020 to 14th November, 2020. A sample size of 93 was calculated by using sustained virologic response in 96% patients using Sofosbuvir and Daclatasvir with the confidence level as 95% and 4% margin of error under WHO formula for sample size determination in health studies. Consecutive non probability sampling technique was used in the study.
RESULTS
Ninety Three treatment naïve hepatitis C patients were included in the study containing 53 males (57%) and 40 females (43%) with mean age of 43 + 0.23. 84 (90%) patients were in Child A class according to Child Pugh score. Overall 89 (95.7%) patients showed sustained virologic response following 12 weeks treatment of naïve HCV patients with combination of sofosbuvir and daclastavir. 5 patients developed side effects to the drugs; 2 patients developed anemia with one patient having anemia severe enough to require blood transfusion. 4 patients did not respond to the treatment regime in terms of sustained virologic response for 12 week treatment and were continued for 24 weeks on the same regime.
CONCLUSION
This study concludes that combined sofosbuvir and daclatasvir for 12 weeks appear to have sustained virologic response in treatment naïve HCV patients. Child score has statistically significant correlation to sustained virologic response with Child A class showing SVR in all patients. Patients in Child class C did not show SVR. Thrombocytopenia has direct and negative affect on SVR.
Downloads
Metrics
References
Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, Yanny I, Razavi H, Vickerman P. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. The Lancet infectious diseases. 2016 Jul 1;16(7):797-808 DOI: https://doi.org/10.1016/S1473-3099(15)00485-5
Arshad A, Ashfaq UA. Epidemiology of hepatitis C infection in Pakistan: current estimate and major risk factors. Crit Rev Eukaryot Gene Expr. 2017;27:63 DOI: https://doi.org/10.1615/CritRevEukaryotGeneExpr.2017018953
Dhingra A, Kapoor S, Alqahtani SA. Recent advances in the treatment of hepatitis C. Discov Med. 2014;18:203e8
Pol S, Corouge M, Pichard VA. Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Hepat Med. 2016;8:21 DOI: https://doi.org/10.2147/HMER.S62014
Bunchorntavakul C, Reddy KR. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2015; 42:258 DOI: https://doi.org/10.1111/apt.13264
Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther. 2014;39:137–47 DOI: https://doi.org/10.1111/apt.12551
Raziky M, Fathalah WF, Akel WA, Salama A, Esmat G, Mabrouk M, et al. The effect of peginterferon alpha-2a vs. peginterferon alpha-2b in treatment of naive chronic hcv genotype-4 patients: A Single Centre Egyptian Study. Hepat Mon. 2013;13(5):10069 DOI: https://doi.org/10.5812/hepatmon.10069
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878 DOI: https://doi.org/10.1056/NEJMoa1214853
Fontaine H, Hezode C, Zoulim F. Efficacy of the oral sofosbuvir based combinations in HCV genotype 4-monoinfected patients from the French observational cohort ANRS CO22 Hepather. Abstract LP28 presented at: 50th Annual Meeting of European Association for the Study of the Liver;2015; Vienna, Austria DOI: https://doi.org/10.1016/S0168-8278(15)30182-3
Haqqi A, Munir R, Khalid M, Khurram M, Zaid M, Ali M, Shah ZH, Ahmed H, Afzal MS. Prevalence of Hepatitis C Virus Genotypes in Pakistan: Current Scenario and Review of Literature. Viral Immunol. 2019 Nov;32(9):402-413 DOI: https://doi.org/10.1089/vim.2019.0058
Omar H, Akel W, Elbaz T. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: realworld results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018;47(3):421 DOI: https://doi.org/10.1111/apt.14428
Ahmed AO, Elsebaey MA, Fouad MHA, Elashry H, Elshafie A, Elhadidy AA, et al. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Inf Drug Res. 2018;11:442 DOI: https://doi.org/10.2147/IDR.S160593
Reid M, Price JC, Tien PC. Hepatitis C virus infection in the older patient. Infect Dis Clin N Am. 2017;31:827–838 DOI: https://doi.org/10.1016/j.idc.2017.07.014
Saab S, Park SH, Mizokami M. Safety and efficacy of ledipasvir/ sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 year or older. Hepatology. 2016;63(4):1112 DOI: https://doi.org/10.1002/hep.28425
Ferenci P, Kozbial K, Mandorfer M, Hofer H. HCV targeting of patients with cirrhosis. J Hepatol. 2015;63:1015 DOI: https://doi.org/10.1016/j.jhep.2015.06.003
Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm–volume 2. J Viral Hepat. 2015;22:26–45 DOI: https://doi.org/10.1111/jvh.12351
Butt N, Anoshia, Khan MA, Akbar A. Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi. Pak J Med Sci. 2021 Nov-Dec;37(7):2014-2019 DOI: https://doi.org/10.12669/pjms.37.7.4627
Cheema SUR, Rehman MS, Hussain G, Cheema SS, Gilani N. Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 &3 in patients undergoing hemodialysis- a prospective interventional clinical trial. BMC Nephrology. 2019;20(1):438 DOI: https://doi.org/10.1186/s12882-019-1631-4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Islam Shah, Nayab Munib, Aliena Badshah, Wazir Mohammad
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
